CAS 141335-10-6

LCB-2853

CAS : 141335-10-6

LCB-2853

Degré de pureté : ≥95%

Masse moléculaire : 421.94g/mol

Ref: 54-BUP21552

LCB-2853

CAS : 141335-10-6

LCB-2853 is a synthetic drug that has been shown to inhibit the biosynthesis of prostaglandins. LCB-2853 was shown to be a potent inhibitor of two major cyclooxygenases, COX-1 and COX-2, in rat erythrocytes and human platelets. It also inhibited TXA2 receptor binding, which leads to suppression of platelet aggregation. LCB-2853 is not active against acetylsalicylic acid or other nonsteroidal antiinflammatory drugs (NSAIDs) and does not activate the TxA2 receptor. This drug has been shown to be effective in animals with muscle injury and can be used for the treatment of muscle pain.
LCB-2853 inhibits the production of prostanoids by blocking COX enzymes and inhibiting TXA2 receptor binding. This causes a decrease in inflammation and pain while also reducing blood clotting.

Formule : C₂₁H₂₄ClNO₄S

Degré de pureté : Min. 95%

Masse moléculaire : 421.9 g/mol

Ref: 3D-RFA33510

LCB-2853

CAS : 141335-10-6

LCB-2853 is a potent thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptor antagonist with antiplatelet aggregation, antivasospasm, and antithrombotic effects.

Formule : C₂₁H₂₄ClNO₄S

Degré de pureté : 97.15%

Couleur et forme : Solid

Masse moléculaire : 421.94

Ref: TM-T11825